An isolation strategy for biomarkers that predict cancer relapse after 5-FU based adjuvant chemotherapy

被引：0
|
作者：
Nishizuka, Satoshi Stephen [1 ]
Ishida, Kazushige [2 ]
Uesugi, Noriyuki [1 ]
Chiba, Takehiro [1 ]
Matsuo, Teppei [1 ]
Yamada, Noriyuki [1 ]
Otsuka, Koki [1 ]
Koeda, Keisuke [1 ]
Sugai, Tamotsu [1 ]
Wakabayashi, Go [1 ]
机构：
[1] Iwate Med Univ, Sch Med, Morioka, Iwate 020, Japan
[2] NCI, Bethesda, MD 20892 USA
来源：
CANCER RESEARCH | 2011年 / 71卷
关键词：
D O I：
10.1158/1538-7445.AM2011-4129
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
4129
引用
收藏
页数：1
相关论文
共 50 条
  • [31] MTHFR polymorphisms and 5-FU-based adjuvant chemotherapy in colorectal cancer
    Afzal, S.
    Jensen, S. A.
    Vainer, B.
    Vogel, U.
    Matsen, J. P.
    Sorensen, J. B.
    Andersen, P. K.
    Poulsen, H. E.
    ANNALS OF ONCOLOGY, 2009, 20 (10) : 1660 - 1666
  • [32] METASTATIC BREAST-CANCER - CHEMOTHERAPY WITH ADRIAMYCIN, VINDESINE, CYCLOPHOSPHAMIDE AND 5-FU - INTEREST OF CONTINUOUS 5-FU INFUSION
    JOUVE, M
    PALANGIE, T
    BELLI, L
    DORVAL, T
    GARCIAGIRALT, E
    BEUZEBOC, P
    SCHOLL, S
    MOSSERI, V
    LIVARTOWSKI, A
    VEDRENNE, J
    POUILLART, P
    BULLETIN DU CANCER, 1989, 76 (06) : 643 - 652
  • [33] Prognostic markers to predict efficacy of 5-FU rechallenge as third line chemotherapy in metastatic colorectal cancer
    Chung, I. -J.
    Kim, K.
    Shim, H. -J.
    Hwang, J. -E.
    Bae, W. K.
    Cho, S. -H.
    ANNALS OF ONCOLOGY, 2016, 27 : 8 - 8
  • [34] Global clinical experience with adjuvant oxaliplatin/5-fluorouracil (5-FU)-based chemotherapy for colon cancer: Outcomes of the ACCElox registry.
    Park, Young Suk
    Ji, Jiafu
    Zalcberg, John Raymond
    Elserafy, Mostafa M.
    Buzaid, Antonio C.
    JOURNAL OF CLINICAL ONCOLOGY, 2013, 31 (15)
  • [35] PROLONGED SURVIVAL (SALVAGE) FOLLOWING RELAPSE ON SINGLE AGENT 5-FU BUT NOT CMF ADJUVANT BREAST-CANCER THERAPY
    CHLEBOWSKI, RT
    WEINER, JM
    REYNOLDS, R
    LUCE, J
    LANG, J
    HESTORFF, R
    GODFREY, T
    BATEMAN, JR
    PROCEEDINGS OF THE AMERICAN ASSOCIATION FOR CANCER RESEARCH, 1984, 25 (MAR): : 174 - 174
  • [36] Incidence, severity, and onset of oral mucositis in 5-FU based chemotherapy for gastrointestinal cancer
    Rosemann, Eva
    Schaefer, H.
    Esmaty, A.
    Stintzing, Sebastian
    Karthaus, Meinolf
    JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (04)
  • [37] Physiologically Based Pharmacokinetic Modeling for Prediction of 5-FU Pharmacokinetics in Cancer Patients with Hepatic Impairment After 5-FU and Capecitabine Administration
    Wang, Yu
    Hu, Haihong
    Yu, Lushan
    Zeng, Su
    PHARMACEUTICAL RESEARCH, 2023,
  • [38] Physiologically Based Pharmacokinetic Modeling for Prediction of 5-FU Pharmacokinetics in Cancer Patients with Hepatic Impairment After 5-FU and Capecitabine Administration
    Yu Wang
    Haihong Hu
    Lushan Yu
    Su Zeng
    Pharmaceutical Research, 2023, 40 (9) : 2177 - 2194
  • [39] Preoperative chemoradiotherapy with 5-fluorouracil (5-FU) or 5-FU/oxaliplatin (5FU/OX) for rectal cancer is a feasible treatment strategy in the elderly
    Dolinsky, C. M.
    Mahmoud, N. N.
    Mick, R.
    Sun, W.
    Whittington, R.
    Solin, L. J.
    Haller, D. G.
    O'Dwyer, P.
    Fry, R. D.
    Metz, J. M.
    INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 2006, 66 (03): : S308 - S308
  • [40] Survival after adjuvant 5-FU treatment for stage III colon cancer in hereditary nonpolyposis colorectal cancer
    Cappel, WHDN
    Meulenbeld, HJ
    Kleibeuker, JH
    Nagengast, FM
    Menko, FH
    Griffioen, G
    Cats, A
    Morreau, H
    Gelderblom, H
    Vasen, HFA
    INTERNATIONAL JOURNAL OF CANCER, 2004, 109 (03) : 468 - 471
12345